CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $50.61B, higher than 95% of all stocks globally
- PositionOperating margin is 46.2%, higher than 95% of its Biotechnology peers (median -34.2%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
71.47TKRW50.61B · vs all stocks (USD)
Trailing P/E
57.98xvs Biotechnology peers
Revenue (TTM)
4.81TKRW3.41B · vs all stocks (USD)
Profit Margin
39.01%vs Biotechnology peers
Beta
0.2140xvs all stocks
52-Week Change
-1.26%vs all stocks
Market Capitalization
71.47TKRW50.61B · vs all stocks (USD)
Enterprise Value
70.33TKRW49.80B · vs all stocks (USD)
Trailing P/E
57.98xvs Biotechnology peers
Forward P/E
31.37xvs Biotechnology peers
PEG Ratio
0.6282xvs Biotechnology peers
Price to Sales (TTM)
14.72xvs Biotechnology peers
Price to Book (MRQ)
9.01xvs Biotechnology peers
Enterprise to Revenue
14.61xvs Biotechnology peers
Enterprise to EBITDA
25.26xvs Biotechnology peers
Gross Margin
54.08%vs Biotechnology peers
Profit Margin
39.01%vs Biotechnology peers
Operating Margin
46.20%vs Biotechnology peers
Return on Assets (TTM)
9.43%vs Biotechnology peers
Return on Equity (TTM)
18.25%vs Biotechnology peers
Revenue (TTM)
4.81TKRW3.41B · vs all stocks (USD)
Revenue per Share (TTM)
110.50KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
25.80%vs Biotechnology peers
Gross Profit (TTM)
2.64TKRW1.87B · vs all stocks (USD)
EBITDA (TTM)
2.86TKRW2.02B · vs all stocks (USD)
Net Income (TTM)
1.75TKRW1.24B · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
24.90%vs Biotechnology peers
Operating Cash Flow (TTM)
2.33TKRW1.65B · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.12TKRW790.79M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
4.56TKRWFY2025 · Dec 31, 2025Cost of Goods Sold
2.04TKRWFY2025 · Dec 31, 2025Gross Profit
2.52TKRWFY2025 · Dec 31, 2025Operating Income
2.07TKRW1.47B · vs all stocks (USD)
Pre-tax Income
2.12TKRWFY2025 · Dec 31, 2025Income Tax Expense
504.30BKRWFY2025 · Dec 31, 2025Net Income
1.78TKRWFY2025 · Dec 31, 2025EBIT
2.15TKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.79TKRWFY2025 · Dec 31, 2025Research & Development
37.18BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
169.63BKRWFY2025 · Dec 31, 2025Other Operating Expenses
20.96BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
46.03BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
29.17BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.78TKRWFY2025 · Dec 31, 2025Operating Cash Flow
1.85TKRWFY2025 · Dec 31, 2025Free Cash Flow
462.01BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
148.85BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.78TKRWFY2025 · Dec 31, 2025Other Non-cash Items
-17.30BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
266.28BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-181.21BKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.39TKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-83.33BKRWFY2025 · Dec 31, 2025Net Acquisitions
16.82BKRWFY2025 · Dec 31, 2025Purchase of Investments
-3.71TKRWFY2025 · Dec 31, 2025Sale of Investments
3.30TKRWFY2025 · Dec 31, 2025Other Investing Activity
-10.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.78TKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
45.00BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-250.00BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-210.00BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-92.01BKRWFY2025 · Dec 31, 2025Other Financing Charges
-216.42BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-723.43BKRWFY2025 · Dec 31, 2025Shares Outstanding
46.24MSharesUpdated Aug 19, 2026Float Shares
11.84MSharesUpdated Aug 19, 2026% Held by Insiders
74.37%vs all stocks
% Held by Institutions
16.42%vs all stocks
Total Cash (MRQ)
1.65TKRW1.17B · vs all stocks (USD)
Total Cash per Share (MRQ)
35.75KKRWUpdated Aug 19, 2026Total Debt (MRQ)
1.19TKRW845.75M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1508xvs Biotechnology peers
Current Ratio (MRQ)
1.70xvs Biotechnology peers
Book Value per Share (MRQ)
171.34KKRWUpdated Aug 19, 2026Total Assets
11.06TKRW7.83B · vs all stocks (USD)
Total Current Assets
4.41TKRWFY2025 · Dec 31, 2025Total Liabilities
3.61TKRWFY2025 · Dec 31, 2025Total Non-current Assets
6.65TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
1.08TKRWFY2025 · Dec 31, 2025Total Current Liabilities
2.53TKRWFY2025 · Dec 31, 2025Cash Equivalents
148.85BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
148.85BKRWFY2025 · Dec 31, 2025Other Short-term Investments
1.34TKRWFY2025 · Dec 31, 2025Accounts Receivable
654.73BKRWFY2025 · Dec 31, 2025Inventory
2.13TKRWFY2025 · Dec 31, 2025Accounts Payable
59.81BKRWFY2025 · Dec 31, 2025Short-term Debt
326.97BKRWFY2025 · Dec 31, 2025Other Current Liabilities
551.92MKRWFY2025 · Dec 31, 2025Long-term Debt
600.12BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
310.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
115.73BKRWFY2025 · Dec 31, 2025Retained Earnings
6.87TKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
7.45TKRW5.28B · vs all stocks (USD)
Treasury Stock
2.91TKRWFY2025 · Dec 31, 202552-Week Low
1.23MKRWUpdated Aug 19, 202652-Week High
1.99MKRWUpdated Aug 19, 202652-Week Change
-1.26%vs all stocks
Beta
0.2140xvs all stocks
50-Day MA
1.41MKRWUpdated Aug 19, 2026200-Day MA
1.60MKRWUpdated Aug 19, 2026Avg 10-Day Volume
50.92KSharesUpdated Aug 19, 2026Avg 30-Day Volume
61.99KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
26.63KKRWUpdated Aug 19, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 46.2%, higher than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: 0.46Industry median: -0.34Industry P95: 0.41Peers compared: 261
Financial Health
Altman Z-Score 14.01: safe zoneNotable
Altman Z-Score: 14.01
High structural barrier to entryNotable
Barrier to Entry: 0.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $50.61B, higher than 95% of all stocks globallySignificant
Market cap (USD): 50,605,904,596.686Global P95: 25,614,208,870.135
Revenue is $3.41B, above the global median of $520.53MNotable
Revenue (USD): 3,408,891,249.804Global Median: 520,528,949.311
Levered free cash flow is $790.79M, above the global median of $16.24MNotable
Levered free cash flow (USD): 790,791,338.176Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Siemens Healthineers AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Edwards Lifesciences Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sun Pharmaceutical Industries Ltd.
Tier 1ProductionApproval-Gated PipelineRule
UCB SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bayer AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Haleon plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Teva Pharmaceutical Industries Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beigene Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
argenx SE
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Pharma Research Products Co., Ltd
7 interpretationsHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated Margin
Promotora y Operadora de Infraestructura, S.A.B. de C.V.
6 interpretationsHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated Margin
NVIDIA Corporation
7 interpretationsHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated Margin